Late HCC onset after DAAs therapy in patients with SVR: a type D ADR that requires a longer follow-up?

Antonella NappiAlessandro PerrellaLuca RinaldiAntonio IzziRodolfo PunziLuigi Elio AdinolfiCostanza SbegliaPasquale BellopedeAdelaide MaddaloniNunzia PapaMicaela Spatarella

Published in: European journal of hospital pharmacy : science and practice (2019)

Keyphrases

adverse drug
emergency department
stem cells
bone marrow
smoking cessation